Back to top

Analyst Blog

Pharmacyclics, Inc. (PCYC - Analyst Report) and Johnson & Johnson (JNJ - Analyst Report) received encouraging news with Imbruvica’s label being expanded in the U.S. as a monotherapy for patients suffering from chronic lymphocytic leukemia (CLL) with a history of receiving at least one prior therapy. Pharmacyclics’ shares were up more than 3% on the news.

The label expansion in the CLL indication has triggered a $60 million milestone payment to Pharmacyclics from Johnson & Johnson.

This is the second approval for Pharmacyclics’ lead and only product, Imbruvica. The drug was earlier approved by the U.S. Food and Drug Administration (FDA) in Nov 2013 as a monotherapy for treating patients suffering from mantle cell lymphoma (MCL). The drug has been approved to treat MCL patients who have been treated at least once for the disease. We note that both the indications for Imbruvica are based on overall response rates, while improvements in survival or disease-related symptoms have not been established.

We are encouraged by Pharmacyclics’ progress with Imbruvica. Imbruvica is currently under review in the EU for CLL and MCL. Meanwhile, companies like Roche (RHHBY - Analyst Report) also have a presence in the CLL market.

Pharmacyclics is also developing Imbruvica for the treatment of multiple myeloma (phase II) and diffuse large B-cell lymphoma (phase II), follicular lymphoma (phase II) and Waldenstrom's macroglobulinemia (phase II).

Pharmacyclics, a biopharma company, currently carries a Zacks Rank #2 (Buy). A better-ranked stock in the same sector is Alexion Pharmaceuticals, Inc. (ALXN - Analyst Report). Alexion holds a Zacks Rank #1 (Strong Buy).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%